当前位置:
X-MOL 学术
›
Lancet Haematol.
›
论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Elotuzumab: no benefit for older patients with newly diagnosed multiple myeloma.
The Lancet Haematology ( IF 24.7 ) Pub Date : 2022-05-09 , DOI: 10.1016/s2352-3026(22)00132-6 Cyrille Touzeau 1
中文翻译:
Elotuzumab:对新诊断的多发性骨髓瘤的老年患者没有益处。
更新日期:2022-05-09
The Lancet Haematology ( IF 24.7 ) Pub Date : 2022-05-09 , DOI: 10.1016/s2352-3026(22)00132-6 Cyrille Touzeau 1
Affiliation
中文翻译:
Elotuzumab:对新诊断的多发性骨髓瘤的老年患者没有益处。